Download full announcement The Company was informed that today, Christopher Mills, a non-executive director, completed the purchase of 3,168 ordinary shares of 0.25 pence each (“Ordinary Shares”) in the Company at a price of 112 pence per share. Following this purchase, Mr Mills is interested in
Download full announcement The Company was informed that today, Christopher Mills, a non-executive director, completed the purchase of 5,970 ordinary shares of 0.25 pence each (“Ordinary Shares”) in the Company at a price of 103 pence per share. Following this purchase, Mr Mills is interested in
Download full announcement NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Renalytix AI Plc 1b.
Download full announcement NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Renalytix AI Plc (LEI:
Download full announcement NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Renalytix AI PLC 1b.
Download full announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence (“AI”) enabled clinical diagnostic solutions for kidney disease, announces that it was yesterday notified that on 6 November 2018 the following PDMR undertook a transaction in the ordinary shares of
Download full announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence (“ AI ”) enabled clinical diagnostic solutions for kidney disease, announces the admission of its ordinary shares (“ Ordinary Shares ”) to trading on AIM (“ Admission ”).
Download full announcement Renalytix AI plc, which develops artificial intelligence (“ AI ”) enabled clinical decision support solutions for kidney disease, announces that, further to the announcement by EKF Diagnostics Holdings plc (“EKF”) on 31 October confirming that RenalytixAI’s had
THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY AND RENALYTIX AI PLC TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER ARTICLE 7 OF REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO
THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY RENALYTIX AI PLC TO CONSTITUTE INSIDE INFORMATION IN RELATION TO THE COMPANY’S QUOTED SECURITIES AS STIPULATED UNDER ARTICLE 7 OF REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE,
